Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 417 articles:
HTML format



Single Articles


    November 2022
  1. CHITADZE G, Stengel A, John-Klaua C, Bruckmuller J, et al
    Somatic TP53 mutations are pre-leukemic events in acute lymphoblastic leukemia.
    Blood. 2022 Nov 30:blood.2022017249. doi: 10.1182/blood.2022017249.
    PubMed    


  2. GHOBADI A, Slade M, Kantarjian H, Alvarenga J, et al
    The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
    Blood. 2022;140:2101-2112.
    PubMed     Abstract available


  3. THIJSSEN R, Tian L, Anderson MA, Flensburg C, et al
    Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
    Blood. 2022;140:2127-2141.
    PubMed     Abstract available


  4. THOMALLA D, Beckmann L, Grimm C, Oliverio M, et al
    Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Blood. 2022;140:2113-2126.
    PubMed     Abstract available


  5. DORES GM, Linet MS, Curtis RE, Morton LM, et al
    Risks of therapy-related hematologic neoplasms beyond myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2022 Nov 15. pii: 493239. doi: 10.1182/blood.2022018051.
    PubMed    


  6. GALLIPOLI P
    AML gets upSET when its dietary needs are unMet.
    Blood. 2022;140:2003-2004.
    PubMed    


  7. MURPHY WJ
    Giving alloHSCT a needed LIF(t).
    Blood. 2022;140:2008-2009.
    PubMed    


  8. CHIBA M, Shimono J, Ishio T, Takei N, et al
    Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
    Blood. 2022;140:1951-1963.
    PubMed     Abstract available


  9. YANG LX, Zhang CT, Yang MY, Zhang XH, et al
    C1Q labels a highly aggressive macrophage-like leukemia population indicating extramedullary infiltration and relapse.
    Blood. 2022 Nov 2. pii: 486969. doi: 10.1182/blood.2022017046.
    PubMed     Abstract available


    October 2022
  10. PANELLI P, De Santis E, Colucci M, Tamiro F, et al
    Noncanonical beta-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia.
    Blood. 2022 Oct 31. pii: 486952. doi: 10.1182/blood.2022017079.
    PubMed     Abstract available


  11. IACOBUCCI I, Mullighan CG
    KMT2A-rearranged leukemia: the shapeshifter.
    Blood. 2022;140:1833-1835.
    PubMed    


  12. AL-ATTAR A, Woda BA
    kappa light chain-expressing hematogones in a patient with lambda-restricted CLL and multiple myeloma on daratumumab therapy.
    Blood. 2022;140:1917.
    PubMed    


  13. WANG ES, Montesinos P, Minden MD, Lee JH, et al
    Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
    Blood. 2022;140:1845-1857.
    PubMed     Abstract available


  14. TIRTAKUSUMA R, Szoltysek K, Milne P, Grinev VV, et al
    Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia.
    Blood. 2022;140:1875-1890.
    PubMed     Abstract available


  15. SHARMA M, Fu MP, Lu HY, Sharma AA, et al
    Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
    Blood. 2022;140:1858-1874.
    PubMed     Abstract available


  16. ZHAO L, Li S, Wei X, Qi X, et al
    A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.
    Blood. 2022;140:1790-1802.
    PubMed     Abstract available


  17. MARTI G
    The clonal evolution and natural history of MBL.
    Blood. 2022;140:1660-1661.
    PubMed    


  18. SLAGER SL, Parikh SA, Achenbach SJ, Norman AD, et al
    Progression and survival of MBL: a screening study of 10 139 individuals.
    Blood. 2022;140:1702-1709.
    PubMed     Abstract available


  19. DOHNER H, Wei AH, Roboz GJ, Montesinos P, et al
    Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
    Blood. 2022;140:1674-1685.
    PubMed     Abstract available


  20. MOUJALLED DM, Brown FC, Chua CC, Dengler MA, et al
    Acquired mutations in BAX confer resistance to BH3-mimetic therapy in Acute Myeloid Leukemia.
    Blood. 2022 Oct 11. pii: 486781. doi: 10.1182/blood.2022016090.
    PubMed     Abstract available


  21. KIPPS TJ
    ROR1: an orphan becomes apparent.
    Blood. 2022;140:1583-1591.
    PubMed     Abstract available


    September 2022
  22. RYLAND G, Umeda M, Holmfeldt L, Lehmann S, et al
    Description of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.
    Blood. 2022 Sep 30. pii: 486718. doi: 10.1182/blood.2022017874.
    PubMed    


  23. BERNT KM
    Do you need the immune system to cure ALL?
    Blood. 2022;140:1457-1458.
    PubMed    



  24. Freeman SD, Valk P. Transplant in older adults with AML: genomic wheat and chaff. Blood. 2022;139(24):3459-3461.
    Blood. 2022;140:1571.
    PubMed    


  25. VAISITTI T, Vitale N, Micillo M, Brandimarte L, et al
    Anti-CD37 alpha-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome.
    Blood. 2022;140:1565-1569.
    PubMed    


  26. IZUTSU K, Makita S, Nosaka K, Yoshimitsu M, et al
    An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma.
    Blood. 2022 Sep 23. pii: 486703. doi: 10.1182/blood.2022016862.
    PubMed     Abstract available


  27. SCHILLER G
    How thinly can one slice the AML diagnostic pie?
    Blood. 2022;140:1330-1331.
    PubMed    


  28. GUINIPERO T, Kahwash SB
    Morphologic findings often provide guidance when immunophenotypic data overlap: a case of AML with cup-shaped nuclei.
    Blood. 2022;140:1448.
    PubMed    


  29. DOHNER H, Wei AH, Appelbaum FR, Craddock C, et al
    Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
    Blood. 2022;140:1345-1377.
    PubMed     Abstract available


  30. ZHANG M, Zhang H, Li Z, Bai L, et al
    Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion.
    Blood. 2022;140:1390-1407.
    PubMed     Abstract available


  31. DUNCAVAGE EJ, Bagg A, Hasserjian RP, DiNardo CD, et al
    Genomic Profiling for Clinical Decision Making in Myeloid Neoplasms and Acute Leukemia.
    Blood. 2022 Sep 21. pii: 486675. doi: 10.1182/blood.2022015853.
    PubMed     Abstract available


  32. KREITMAN RJ, Moreau P, Ravandi F, Hutchings M, et al
    Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
    Blood. 2022 Sep 15. pii: 486621. doi: 10.1182/blood.2021013658.
    PubMed     Abstract available


  33. MAESE LD, Loh ML, Choi MR, Lin T, et al
    Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia: Results from the Phase 2/3 AALL1931 Study.
    Blood. 2022 Sep 15. pii: 486644. doi: 10.1182/blood.2022016923.
    PubMed     Abstract available


  34. PENTER L, Wu CJ
    AML relapse after a TIGIT race.
    Blood. 2022;140:1189-1191.
    PubMed    



  35. Duault C, Kumar A, Taghi Khani A, et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480.
    Blood. 2022;140:1326-1327.
    PubMed    


  36. BARILA' G, Grassi A, Cheon H, Teramo A, et al
    Tgammadelta LGL LEUKEMIA IDENTIFIES A SUBSET WITH MORE SYMPTOMATIC DISEASE: ANALYSIS OF AN INTERNATIONAL COHORT OF 137 PATIENTS.
    Blood. 2022 Sep 12. pii: 486580. doi: 10.1182/blood.2021013489.
    PubMed     Abstract available


  37. NAGLER A, Wu CJ
    The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL).
    Blood. 2022 Sep 12. pii: 486574. doi: 10.1182/blood.2021014669.
    PubMed     Abstract available


  38. WU HC, de The H
    In APL, noncoding mutations and SNP converge on WT1.
    Blood. 2022;140:1060-1061.
    PubMed    


  39. PHILIPP N, Kazerani M, Nicholls A, Vick B, et al
    T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
    Blood. 2022;140:1104-1118.
    PubMed     Abstract available


    August 2022
  40. MO F, Watanabe N, Ingersoll Omdahl K, Burkhardt PM, et al
    Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation.
    Blood. 2022 Aug 31. pii: 486464. doi: 10.1182/blood.2022016052.
    PubMed     Abstract available


  41. KITTAI AS, Woyach JA
    uMRD: "the" endpoint or "an" endpoint for CLL?
    Blood. 2022;140:797-798.
    PubMed    


  42. OBENG EA
    Mutant SF3B1 splices a more leukemogenic EVI1.
    Blood. 2022;140:800-801.
    PubMed    


  43. SEYMOUR JF, Kipps TJ, Eichhorst BF, D'Rozario J, et al
    Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Blood. 2022;140:839-850.
    PubMed     Abstract available


  44. CUNNINGHAM A, Erdem A, Alshamleh I, Geugien M, et al
    Dietary methionine starvation impairs acute myeloid leukemia progression.
    Blood. 2022 Aug 19. pii: 486352. doi: 10.1182/blood.2022017575.
    PubMed     Abstract available


  45. CAPPELLI LV, Fiore D, Phillip JM, Yoffe L, et al
    Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.
    Blood. 2022 Aug 18. pii: 486319. doi: 10.1182/blood.2022015414.
    PubMed     Abstract available


  46. WANG J, Chang CY, Yang X, Zhou F, et al
    Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity.
    Blood. 2022 Aug 18. pii: 486317. doi: 10.1182/blood.2022015677.
    PubMed     Abstract available


  47. RIO-MACHIN A, Fitzgibbon J
    DDX41: the poster child for familial AML.
    Blood. 2022;140:667-669.
    PubMed    


  48. LI P, Brown S, Williams M, White T, et al
    The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.
    Blood. 2022;140:716-755.
    PubMed     Abstract available


  49. WAGNER DL
    The uncut version: base-edited allo-CAR T cells.
    Blood. 2022;140:526-527.
    PubMed    


  50. DEAGLIO S
    Glutamine and CLL: ready for prime time?
    Blood. 2022;140:528-529.
    PubMed    


  51. DIORIO C, Murray R, Naniong M, Barrera L, et al
    Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
    Blood. 2022;140:619-629.
    PubMed     Abstract available


  52. CARRATT SA, Kong GL, Curtiss BM, Schonrock Z, et al
    Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Blood. 2022;140:644-658.
    PubMed     Abstract available


  53. HANDA S, Lee JO, Derkach A, Stone RM, et al
    Long Term Outcomes in Patients with Relapsed or Refractory Hairy Cell Leukemia Treated with Vemurafenib Monotherapy.
    Blood. 2022 Aug 5. pii: 486128. doi: 10.1182/blood.2022016183.
    PubMed     Abstract available


  54. IACOBUCCI I, Witkowski MT, Mullighan CG
    Single-cell analysis of acute lymphoblastic and lineage ambiguous leukemia - approaches and molecular insights.
    Blood. 2022 Aug 4. pii: 486119. doi: 10.1182/blood.2022016954.
    PubMed     Abstract available


  55. VOSO MT, Buccisano F
    AML: making residual disease more measurable.
    Blood. 2022;140:415-417.
    PubMed    


  56. SCARFO L, Herishanu Y
    CLL and COVID-19: light at the end of the tunnel?
    Blood. 2022;140:407-409.
    PubMed    


  57. LI SQ, Xu LP, Wang Y, Zhang XH, et al
    An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.
    Blood. 2022;140:516-520.
    PubMed    


  58. SHALABI H, Qin H, Su A, Yates B, et al
    CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
    Blood. 2022;140:451-463.
    PubMed     Abstract available


  59. NIEMANN CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, et al
    Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
    Blood. 2022;140:445-450.
    PubMed     Abstract available


  60. CICHOCKI F, Goodridge J, Bjordahl R, Mahmood S, et al
    Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia.
    Blood. 2022 Aug 2. pii: 486089. doi: 10.1182/blood.2021015184.
    PubMed     Abstract available


    July 2022
  61. VELASQUEZ MP, Mamonkin M
    CD7 CAR: sword and shield.
    Blood. 2022;140:293-294.
    PubMed    


  62. GERDEMANN U, Alvarez-Calderon F
    Uncovering CD4+ T-cell exhaustion in B-ALL.
    Blood. 2022;140:294-296.
    PubMed    


  63. LU P, Liu Y, Yang J, Zhang X, et al
    Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial.
    Blood. 2022;140:321-334.
    PubMed     Abstract available


  64. BLACK GS, Huang X, Qiao Y, Tarapcsak S, et al
    Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
    Blood. 2022;140:401-405.
    PubMed    


  65. KRAMER MH, Zhang Q, Sprung R, Day RB, et al
    Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia.
    Blood. 2022 Jul 27. pii: 486036. doi: 10.1182/blood.2022016033.
    PubMed     Abstract available


  66. ZEIDAN AM, Fenaux P, Gobbi M, Mayer J, et al
    Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
    Blood. 2022;140:285-289.
    PubMed    


  67. HO JG, Schmidt D, Lowinus T, Ryoo J, et al
    Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
    Blood. 2022 Jul 19. pii: 485955. doi: 10.1182/blood.2022016082.
    PubMed     Abstract available


  68. EICHHORST B
    Ibrutinib frontline in young patients with CLL.
    Blood. 2022;140:80-81.
    PubMed    


  69. XU K, Nacheva E
    Secondary AML with MLL gene amplification.
    Blood. 2022;140:161.
    PubMed    


  70. SHANAFELT TD, Wang XV, Hanson CA, Paietta EM, et al
    Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
    Blood. 2022;140:112-120.
    PubMed     Abstract available


  71. JANSSEN M, Schmidt C, Bruch PM, Blank MF, et al
    Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1.
    Blood. 2022 Jul 13. pii: 485887. doi: 10.1182/blood.2021014241.
    PubMed     Abstract available


  72. GOURNAY V, Vallet N, Peux V, Vera K, et al
    Immune landscape after allo-HSCT: TIGIT and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse.
    Blood. 2022 Jul 12. pii: 485877. doi: 10.1182/blood.2022015522.
    PubMed     Abstract available


  73. DIORIO C, Teachey DT
    Please eat me! Targeting CD47 and CD38 in T-ALL.
    Blood. 2022;140:6-8.
    PubMed    


  74. GOWER M, Tikhonova AN
    Avoiding fratricide: a T-ALL order.
    Blood. 2022;140:3-4.
    PubMed    


  75. HASSERJIAN RP
    Revealing the dark secrets of TP53-mutated AML.
    Blood. 2022;140:8-10.
    PubMed    


  76. MULLER K, Vogiatzi F, Winterberg D, Rosner T, et al
    Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL.
    Blood. 2022;140:45-57.
    PubMed     Abstract available


    June 2022
  77. THAKRAL B, Bueso-Ramos CE
    Unexpected presentation of cold agglutinin syndrome with B-acute lymphoblastic leukemia.
    Blood. 2022;139:3778.
    PubMed    


  78. BARTH BM
    Ceramide: improving Bcl-2 inhibitor therapy.
    Blood. 2022;139:3676-3678.
    PubMed    


  79. WANG H, He X, Zhang L, Dong H, et al
    Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade.
    Blood. 2022;139:3752-3770.
    PubMed     Abstract available


  80. ARBER DA, Orazi A, Hasserjian RP, Borowitz MJ, et al
    International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.
    Blood. 2022 Jun 29. pii: 485730. doi: 10.1182/blood.2022015850.
    PubMed     Abstract available


  81. QIU L, Quesada AE
    Plasma cell leukemia with small cell morphology.
    Blood. 2022;139:3667.
    PubMed    



  82. Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020;135(11):866-870.
    Blood. 2022;139:3669.
    PubMed    


  83. TANAKA A, Nakano TA, Nomura M, Yamazaki H, et al
    Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
    PubMed     Abstract available


  84. FIORETOS T
    Why B(-)other? About the gap of unknowns in ALL.
    Blood. 2022;139:3455-3457.
    PubMed    


  85. FREEMAN SD, Valk P
    Transplant in older adults with AML: genomic wheat and chaff.
    Blood. 2022;139:3459-3461.
    PubMed    



  86. Genetics and outcome in older AML transplant.
    Blood. 2022;139:3559.
    PubMed    


  87. YEUNG DT, Shanmuganathan N, Hughes TP
    Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Blood. 2022;139:3474-3479.
    PubMed     Abstract available


  88. PASSET M, Kim R, Gachet S, Sigaux F, et al
    Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
    Blood. 2022;139:3505-3518.
    PubMed     Abstract available


  89. MURDOCK HM, Kim HT, Denlinger N, Vachhani P, et al
    Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
    Blood. 2022;139:3546-3557.
    PubMed     Abstract available


  90. CHEMINANT M, Lhermitte L, Bruneau J, Sicard H, et al
    KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.
    Blood. 2022 Jun 10. pii: 485527. doi: 10.1182/blood.2022016765.
    PubMed     Abstract available


  91. ALVAREZ S, da Silva Almeida AC, Albero R, Biswas M, et al
    Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair.
    Blood. 2022;139:3418-3429.
    PubMed     Abstract available


  92. PERL AE, Larson RA, Podoltsev NA, Strickland S, et al
    Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Blood. 2022;139:3366-3375.
    PubMed     Abstract available


  93. LI Y, Yang X, Sun Y, Li Z, et al
    The Impact of T cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia.
    Blood. 2022 Jun 8. pii: 485490. doi: 10.1182/blood.2021014495.
    PubMed     Abstract available


  94. ROBIN M, de Wreede LC, Padron E, Bakunina K, et al
    Role of Allogeneic Transplantation In Chronic Myelomonocytic Leukemia: An International Collaborative Analysis.
    Blood. 2022 Jun 6. pii: 485477. doi: 10.1182/blood.2021015173.
    PubMed     Abstract available


  95. SONG H, Liu Y, Tan Y, Zhang Y, et al
    Recurrent non-coding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia.
    Blood. 2022 Jun 2. pii: 485457. doi: 10.1182/blood.2021014945.
    PubMed     Abstract available


  96. ROGERS KA, Woyach JA
    A CAPTIVATE-ing new regimen for CLL.
    Blood. 2022;139:3229-3230.
    PubMed    


  97. FERNANDEZ-SEVILLA LM, Valencia J, Ortiz-Sanchez P, Fraile-Ramos A, et al
    High BMP4 expression in low/intermediate risk BCP-ALL identifies children with poor outcomes.
    Blood. 2022;139:3303-3313.
    PubMed     Abstract available


  98. TAM CS, Allan JN, Siddiqi T, Kipps TJ, et al
    Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Blood. 2022;139:3278-3289.
    PubMed     Abstract available


    May 2022

  99. Genomic landscape of T-LGL leukemia.
    Blood. 2022;139:3100.
    PubMed    


  100. SEMENZATO G, Zambello R
    Interrogating molecular genetics to refine LGLL classification.
    Blood. 2022;139:3002-3004.
    PubMed    


  101. LAUKKANEN S, Bacquelaine Veloso A, Yan C, Oksa L, et al
    Combination therapies to inhibit LCK tyrosine kinase and mTOR signaling in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 11. pii: 485213. doi: 10.1182/blood.2021015106.
    PubMed     Abstract available


  102. BIEDERSTADT A, Rezvani K
    How I treat high-risk acute myeloid leukemia using pre-emptive adoptive cellular immunotherapy.
    Blood. 2022 May 5. pii: 485176. doi: 10.1182/blood.2021012411.
    PubMed     Abstract available



  103. Tomizawa D, Miyamura T, Imamura T, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813-1823.
    Blood. 2022;139:2848.
    PubMed    


  104. LI L, Kim JH, Lu W, Williams DM, et al
    HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.
    Blood. 2022;139:2797-2815.
    PubMed     Abstract available


  105. TYAGI A, Ly S, El-Dana F, Yuan B, et al
    Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.
    Blood. 2022;139:2782-2796.
    PubMed     Abstract available


  106. FREY NV
    Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
    Blood. 2022 May 4. pii: 485154. doi: 10.1182/blood.2021014892.
    PubMed     Abstract available


  107. MACIOCIA PM, Wawrzyniecka PA, Maciocia NC, Burley A, et al
    Anti-CCR9 Chimeric Antigen Receptor T cells for T Cell Acute Lymphoblastic Leukemia.
    Blood. 2022 May 4. pii: 485152. doi: 10.1182/blood.2021013648.
    PubMed     Abstract available


    April 2022
  108. CHEN Z, Simon-Molas H, Cretenet G, Valle-Argos B, et al
    Characterization of metabolic alterations of Chronic Lymphocytic Leukemia in the lymph node microenvironment.
    Blood. 2022 Apr 29. pii: 485126. doi: 10.1182/blood.2021013990.
    PubMed     Abstract available


  109. BISHOP MR
    New hope to prevent ALL relapse after transplant.
    Blood. 2022;139:2580-2581.
    PubMed    


  110. ZHAO Y, Wang E
    Pure erythroid leukemia evolved from JAK2V617F-positive polycythemia vera: blast phase transformation along erythroid line.
    Blood. 2022;139:2574.
    PubMed    


  111. CHIANG MY
    Firing up chromatin to forge T-ALL.
    Blood. 2022;139:2418-2420.
    PubMed    


  112. ANTOSZEWSKI M, Fournier N, Ruiz Buendia GA, Lourenco J, et al
    Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.
    Blood. 2022;139:2483-2498.
    PubMed     Abstract available


  113. DUPLOYEZ N, Largeaud L, Duchmann M, Kim R, et al
    Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study.
    Blood. 2022 Apr 20. pii: 485005. doi: 10.1182/blood.2021015328.
    PubMed     Abstract available


  114. LEWIS AC, Pope VS, Tea MN, Li M, et al
    Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
    Blood. 2022 Apr 20. pii: 485003. doi: 10.1182/blood.2021013277.
    PubMed     Abstract available


  115. WELCH JS
    TP53 and the star-crossed lovers MDS and AML.
    Blood. 2022;139:2265-2266.
    PubMed    


  116. TASHAKORI M, Kadia TM, Loghavi S, Daver NG, et al
    TP53 Copy Number and Protein Expression Inform Mutation Status across Risk Categories in Acute Myeloid Leukemia.
    Blood. 2022 Apr 7. pii: 484631. doi: 10.1182/blood.2021013983.
    PubMed     Abstract available


  117. DANILOV AV
    Immunity in CLL: corrupt at inception?
    Blood. 2022;139:2104-2105.
    PubMed    


  118. DEPASQUALE EAK, van Galen P
    Plasticity and immune evasion in childhood ALL.
    Blood. 2022;139:2096-2097.
    PubMed    


  119. PURROY N, Tong YE, Lemvigh CK, Cieri N, et al
    Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
    Blood. 2022;139:2252-2256.
    PubMed    


  120. ROBOZ GJ, Ravandi F, Wei AH, Dombret H, et al
    Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
    Blood. 2022;139:2145-2155.
    PubMed     Abstract available


  121. LEAHY AB, Devine KJ, Li Y, Liu H, et al
    Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
    Blood. 2022;139:2173-2185.
    PubMed     Abstract available


    March 2022
  122. BELLUSCI L, Grubbs G, Srivastava P, Nemeth MJ, et al
    Neutralization of SARS-CoV-2 Omicron after vaccination of myelodysplastic syndromes and acute myeloid leukemia patients.
    Blood. 2022 Mar 28. pii: 484507. doi: 10.1182/blood.2022016087.
    PubMed    


  123. QI Y, Zhao M, Hu Y, Wang Y, et al
    Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Blood. 2022 Mar 25. pii: 484499. doi: 10.1182/blood.2021013733.
    PubMed     Abstract available


  124. WANG HY, Heyman BM
    Annexin A1- but CD10+ hairy cell leukemia.
    Blood. 2022;139:1924.
    PubMed    


  125. KATER AP, Melenhorst JJ
    Do CARs finally hit the CLL road?
    Blood. 2022;139:1775-1776.
    PubMed    


  126. SIDDIQI T, Soumerai JD, Dorritie KA, Stephens DM, et al
    Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
    Blood. 2022;139:1794-1806.
    PubMed     Abstract available


  127. BUCHMANN S, Schrappe M, Baruchel A, Biondi A, et al
    Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
    Blood. 2022;139:1785-1793.
    PubMed     Abstract available


  128. BEWERSDORF JP, Patel KK, Goshua G, Shallis RM, et al
    Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia.
    Blood. 2022;139:1766-1770.
    PubMed    


  129. PARAS G, Morsink LM, Othus M, Milano F, et al
    Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML.
    Blood. 2022;139:1694-1706.
    PubMed     Abstract available


  130. BEDNARSKI JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, et al
    Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
    Blood. 2022;139:1670-1683.
    PubMed     Abstract available


  131. PARIHAR R
    Memory NK cells to forget relapsed AML.
    Blood. 2022;139:1607-1608.
    PubMed    


  132. KLEPIN HD
    Toward consensus on geriatric assessment in AML.
    Blood. 2022;139:1605-1606.
    PubMed    


  133. MIN GJ, Cho BS, Park SS, Park S, et al
    Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML.
    Blood. 2022;139:1646-1658.
    PubMed     Abstract available


  134. TRACY SI, Venkatesh H, Hekim C, Heltemes Harris LM, et al
    Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.
    Blood. 2022 Mar 11. pii: 484383. doi: 10.1182/blood.2021015341.
    PubMed     Abstract available


  135. MATSUOKA M
    Targeting vulnerabilities of adult T-cell leukemia.
    Blood. 2022;139:1435.
    PubMed    


  136. NEDUMANNIL R, Juneja S
    Pseudo-Chediak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.
    Blood. 2022;139:1598.
    PubMed    



  137. Silva O, Kurzer J. Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations. Blood. 2021;138(9):818.
    Blood. 2022;139:1602.
    PubMed    


  138. MARTI G
    Premonoclonal B-cell lymphocytosis: the CLL cell of origin.
    Blood. 2022;139:1436-1437.
    PubMed    


  139. STIVERS N, Afify Z
    Pediatric B-acute lymphoblastic leukemia presenting with a mass: an underrecognized association.
    Blood. 2022;139:1423.
    PubMed    



  140. Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138(19):1885-1895.
    Blood. 2022;139:1424-1425.
    PubMed    


  141. KWOK M, Stankovic T
    The three musketeers: uniting against CLL.
    Blood. 2022;139:1264-1265.
    PubMed    


  142. VERRILLS NM
    PP2A activation targets AML stem cells.
    Blood. 2022;139:1267-1269.
    PubMed    


    February 2022
  143. MAITI A, Daver NG
    A nonstick marrow may help to fry leukemia.
    Blood. 2022;139:1119-1121.
    PubMed    



  144. Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021;137(19):2585-2597.
    Blood. 2022;139:1257.
    PubMed    


  145. BROWN AL
    And the germline beat (AML) goes on.
    Blood. 2022;139:1126-1128.
    PubMed    


  146. BERRIEN-ELLIOTT MM, Becker-Hapak M, Cashen AF, Jacobs M, et al
    Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
    Blood. 2022;139:1177-1183.
    PubMed     Abstract available


  147. YANG F, Long N, Anekpuritanang T, Bottomly D, et al
    Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.
    Blood. 2022;139:1208-1221.
    PubMed     Abstract available


  148. BLOMBERY P, Lew TE, Dengler MA, Thompson ER, et al
    Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
    Blood. 2022;139:1198-1207.
    PubMed     Abstract available


  149. SIPOL A, Hameister E, Xue B, Hofstetter J, et al
    MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.
    Blood. 2022;139:1184-1197.
    PubMed     Abstract available


  150. KIMURA S, Montefiori L, Iacobucci I, Zhao Y, et al
    Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
    Blood. 2022 Feb 22. pii: 484108. doi: 10.1182/blood.2022015444.
    PubMed     Abstract available


  151. BANGHAM CRM
    Adult T-cell leukemia: genomic analysis.
    Blood. 2022;139:953-954.
    PubMed    


  152. YOU X, Liu F, Binder M, Vedder A, et al
    Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    Blood. 2022;139:1066-1079.
    PubMed     Abstract available


  153. CAZAUBIEL T, Leleu X, Perrot A, Manier S, et al
    Primary Plasma Cell Leukemia displaying t(11;14) have specific genomic, transcriptional and clinical feature.
    Blood. 2022 Feb 16. pii: 484066. doi: 10.1182/blood.2021014968.
    PubMed     Abstract available


  154. FALINI B, De Carolis L, Tiacci E
    How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Blood. 2022 Feb 10. pii: 483952. doi: 10.1182/blood.2021013502.
    PubMed     Abstract available


  155. WILL B
    Fighting AML with its own weapons.
    Blood. 2022;139:807-809.
    PubMed    


  156. MILL CP, Fiskus W, DiNardo CD, Birdwell C, et al
    Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Blood. 2022;139:907-921.
    PubMed     Abstract available


  157. HEIKAMP EB, Henrich JA, Perner F, Wong EM, et al
    The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML.
    Blood. 2022;139:894-906.
    PubMed     Abstract available


  158. NAIK S, Vasileiou S, Tzannou I, Kuvalekar M, et al
    Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.
    Blood. 2022 Feb 8. pii: 483888. doi: 10.1182/blood.2021014648.
    PubMed     Abstract available


  159. LV K, Tong W
    Waking up CML leukemia stem cells for the kill.
    Blood. 2022;139:647-648.
    PubMed    


  160. WANG XQ, McGinnis E
    Megakaryocytic emperipolesis as a dyshematopoietic feature in acute myeloid leukemia with inv(16).
    Blood. 2022;139:798.
    PubMed    


  161. BHAT SA, Woyach JA
    Boosting BNT162b2 vaccine efficacy in CLL.
    Blood. 2022;139:639-640.
    PubMed    


  162. DEAGLIO S, Vaisitti T
    A new taxonomy for splenic marginal zone lymphoma.
    Blood. 2022;139:644-645.
    PubMed    


  163. HERISHANU Y, Rahav G, Levi S, Braester A, et al
    Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Blood. 2022;139:678-685.
    PubMed     Abstract available


  164. DAVIDS MS, Rogers KA, Tyekucheva S, Wang Z, et al
    Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
    Blood. 2022;139:686-689.
    PubMed     Abstract available


  165. SASAKI K, Yamauchi T, Semba Y, Nogami J, et al
    Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Blood. 2022;139:748-760.
    PubMed     Abstract available


  166. GROB T, Al Hinai AS, Sanders MA, Kavelaars F, et al
    MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME.
    Blood. 2022 Feb 2. pii: 483799. doi: 10.1182/blood.2021014472.
    PubMed     Abstract available


    January 2022
  167. PETERS FS, Kater AP
    Increasing CART cell engine performance in CLL.
    Blood. 2022;139:473-474.
    PubMed    


  168. FUNK CR, Wang S, Chen KZ, Waller A, et al
    PI3Kdelta/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
    Blood. 2022;139:523-537.
    PubMed     Abstract available


  169. MAN CH, Mercier FE, Liu N, Dong W, et al
    Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive normal and malignant cell growth.
    Blood. 2022;139:502-522.
    PubMed     Abstract available


  170. ABRAHAM IE, Rauscher GH, Patel AA, Pearse W, et al
    Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
    Blood. 2022 Jan 21. pii: 483615. doi: 10.1182/blood.2021012830.
    PubMed     Abstract available


  171. LEE EJ, Bussel JB
    An "ATRA-ctive" new treatment of ITP?
    Blood. 2022;139:307-308.
    PubMed    


  172. SOMMERKAMP P, Trumpp A
    Driving differentiation: targeting APA in AML.
    Blood. 2022;139:317-319.
    PubMed    


  173. MCCORMACK MP
    T/myeloid MPAL: origin and pathogenesis.
    Blood. 2022;139:313-315.
    PubMed    


  174. AARAKAKI H, Karube K
    Small-cell pattern of DUSP22 rearranged ALK-negative anaplastic large-cell lymphoma with leukemic phase.
    Blood. 2022;139:465.
    PubMed    


  175. ESTEY E, Hasserjian RP, Dohner H
    Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.
    Blood. 2022;139:323-332.
    PubMed     Abstract available


  176. WARREN AJ
    Road to RIO-kinase 2 for AML therapy.
    Blood. 2022;139:156-157.
    PubMed    


  177. WANG W, Hu Z
    Leukocytosis with left-shifted myeloid maturation in a peripheral blood specimen: a clue to the lymphoid blast phase of CML.
    Blood. 2022;139:305.
    PubMed    


  178. BRENDOLAN A, Russo V
    Targeting cholesterol homeostasis in hematopoietic malignancies.
    Blood. 2022;139:165-176.
    PubMed     Abstract available


  179. FUJIHARA M, Sakata R, Yoshida N, Ozasa K, et al
    Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.
    Blood. 2022;139:217-227.
    PubMed     Abstract available


  180. CHEON H, Xing JC, Moosic KB, Ung J, et al
    Genomic Landscape of TCR Alpha-Beta and TCR Gamma-Delta T-Large Granular Lymphocyte Leukemia.
    Blood. 2022 Jan 11. pii: 483429. doi: 10.1182/blood.2021013164.
    PubMed     Abstract available


  181. ZHANG YH, Han X
    Acute promyelocytic leukemia with Chediak-Higashi like giant granules.
    Blood. 2022;139:149.
    PubMed    


  182. BULLINGER L
    CEBPA mutations in AML: site matters.
    Blood. 2022;139:6-7.
    PubMed    


  183. YOUNG PE, Medeiros LJ
    Unexpected myeloid sarcoma of the tonsil in a patient without a history of hematological neoplasm.
    Blood. 2022;139:148.
    PubMed    


    December 2021
  184. VOLK A
    Ticket to divide: m6A reader YTHDC1 drives acute myeloid leukemia proliferation.
    Blood. 2021;138:2748-2750.
    PubMed    


  185. MORENO C, Mora A
    MRD in CLL: some answers, many questions.
    Blood. 2021;138:2746-2747.
    PubMed    


  186. TRAN A, Wong M
    Atypical CML with mutated SRSF2, ASXL1, CSF3R, and MPL.
    Blood. 2021;138:2890.
    PubMed    


  187. WANG XV, Hanson CA, Tschumper RC, Lesnick CE, et al
    Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
    Blood. 2021;138:2810-2827.
    PubMed     Abstract available


  188. SHENG Y, Wei J, Yu F, Xu H, et al
    A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication.
    Blood. 2021;138:2838-2852.
    PubMed     Abstract available


  189. CAI H, Kondo M, Sandhow L, Xiao P, et al
    Critical Role of Lama4 for Hematopoiesis Regeneration and Acute Myeloid Leukemia Progression.
    Blood. 2021 Dec 27. pii: 483253. doi: 10.1182/blood.2021011510.
    PubMed     Abstract available


  190. POZDNYAKOVA O
    NPM1: not present? Mark!
    Blood. 2021;138:2602-2603.
    PubMed    


  191. AL-SAWAF O, Fischer K
    TP53 mutations in CLL: does frequency matter?
    Blood. 2021;138:2600-2601.
    PubMed    


  192. UY GL
    Turning AML targets inside out.
    Blood. 2021;138:2598-2599.
    PubMed    


  193. TEN HACKEN E, Wu CJ
    Understanding CLL biology through mouse models of human genetics.
    Blood. 2021;138:2621-2631.
    PubMed     Abstract available


  194. RIGOLIN GM, Del Giudice I, Bardi A, Melandri A, et al
    Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
    Blood. 2021;138:2727-2730.
    PubMed    


  195. MARTELLI MP, Rossi R, Venanzi A, Meggendorfer M, et al
    Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
    Blood. 2021;138:2696-2701.
    PubMed     Abstract available


  196. AUGSBERGER C, Hanel G, Xu W, Pulko V, et al
    Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Blood. 2021;138:2655-2669.
    PubMed     Abstract available


  197. MALCIKOVA J, Pavlova S, Barbara KV, Radova L, et al
    Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
    Blood. 2021;138:2670-2685.
    PubMed     Abstract available


  198. GABALLA MR, Banerjee PP, Milton DR, Jiang X, et al
    Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.
    Blood. 2021 Dec 16. pii: 483090. doi: 10.1182/blood.2021013290.
    PubMed     Abstract available


  199. SHOPSOWITZ KE, Slack GW
    B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion.
    Blood. 2021;138:2593.
    PubMed    


  200. SIVINA M, Kim E, Wierda WG, Ferrajoli A, et al
    Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations.
    Blood. 2021;138:2589-2592.
    PubMed    


  201. TONC E, Takeuchi Y, Chou C, Xia Y, et al
    Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.
    Blood. 2021;138:2526-2538.
    PubMed     Abstract available


  202. HUBER H, Edenhofer S, von Tresckow J, Robrecht S, et al
    Phase 2 study of obinutuzumab (GA-101), ibrutinib and venetoclax (CLL2-GIVe) in patients with untreated high-risk chronic lymphocytic leukemia.
    Blood. 2021 Dec 15. pii: 483086. doi: 10.1182/blood.2021013208.
    PubMed     Abstract available


  203. ROSENQUIST R
    The more complex, the worse outcome in CLL.
    Blood. 2021;138:2305-2307.
    PubMed    


  204. THAKRAL B, Lin P
    Acute myeloid leukemia with erythroid and megakaryocytic differentiation associated with Down syndrome.
    Blood. 2021;138:2446.
    PubMed    


  205. HITZLER J, Alonzo T, Gerbing R, Beckman A, et al
    High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
    Blood. 2021;138:2337-2346.
    PubMed     Abstract available


  206. KITTAI AS, Miller C, Goldstein D, Huang Y, et al
    The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Blood. 2021;138:2372-2382.
    PubMed     Abstract available


  207. LI Y, Xie X, Jie Z, Zhu L, et al
    DYRK1a mediates BAFF-induced noncanonical NF-kappaB activation to promote autoimmunity and B-cell leukemogenesis.
    Blood. 2021;138:2360-2371.
    PubMed     Abstract available


  208. WEEKS LD, Marinac CR, Redd RA, Abel GA, et al
    Age-related Diseases of Inflammation in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
    Blood. 2021 Dec 7. pii: 482919. doi: 10.1182/blood.2021014418.
    PubMed    


  209. CHEN C, Yu W, Alikarami F, Qiu Q, et al
    Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia.
    Blood. 2021 Dec 5. pii: 482898. doi: 10.1182/blood.2021013442.
    PubMed     Abstract available


  210. BHATIA R
    Fattening up FLT3-ITD for the kill.
    Blood. 2021;138:2158-2159.
    PubMed    


    November 2021
  211. SCHWALLER J
    MLL-AF4+ infant leukemia: a microRNA affair.
    Blood. 2021;138:2014-2015.
    PubMed    


  212. JACOBS JW, Siddon AJ
    Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
    Blood. 2021;138:2154.
    PubMed    


  213. REA D, Mauro MJ, Boquimpani C, Minami Y, et al
    A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Blood. 2021;138:2031-2041.
    PubMed     Abstract available


  214. ROSSI M, Meggendorfer M, Zampini M, Tettamanti M, et al
    Clinical relevance of clonal hematopoiesis in persons aged >/=80 years.
    Blood. 2021;138:2093-2105.
    PubMed     Abstract available


  215. MARCAULT C, Zhao LP, Maslah N, Verger E, et al
    Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
    Blood. 2021;138:2142-2148.
    PubMed    


  216. ISHIO T, Kumar S, Shimono J, Daenthanasanmak A, et al
    Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
    Blood. 2021 Nov 24. pii: 482776. doi: 10.1182/blood.2021012734.
    PubMed     Abstract available


  217. ZHONG W, Cao X, Pan G, Niu Q, et al
    ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1.
    Blood. 2021 Nov 19. pii: 482705. doi: 10.1182/blood.2021013579.
    PubMed     Abstract available


  218. GOSWAMI S, Mani R, Nunes J, Chiang CL, et al
    PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
    Blood. 2021 Nov 17. pii: 482661. doi: 10.1182/blood.2020010344.
    PubMed     Abstract available


  219. ZHAO H, Pomicter AD, Eiring AM, Franzini A, et al
    MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common beta Chain Cytokine Receptor Endocytosis.
    Blood. 2021 Nov 15. pii: 477970. doi: 10.1182/blood.2021011802.
    PubMed     Abstract available


  220. THOMAS D
    Machine learning finds new AML subtypes.
    Blood. 2021;138:1790-1792.
    PubMed    


  221. DE BOCK CE, Cools J
    BETter insight into PRC2-mutated T-ALL.
    Blood. 2021;138:1787-1788.
    PubMed    


  222. CHOI MY
    Improving the outlook for TP53-aberrant CLL.
    Blood. 2021;138:1785-1786.
    PubMed    


  223. ANDRIEU GP, Kohn M, Simonin M, Smith CL, et al
    PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.
    Blood. 2021;138:1855-1869.
    PubMed     Abstract available


  224. CRAMER P, Tausch E, von Tresckow J, Giza A, et al
    Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
    Blood. 2021;138:1805-1816.
    PubMed     Abstract available


  225. MHIBIK M, Gaglione EM, Eik D, Kendall EK, et al
    BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
    Blood. 2021;138:1843-1854.
    PubMed     Abstract available


  226. LANGERBEINS P, Zhang C, Robrecht S, Cramer P, et al
    The CLL12 trial: Ibrutinib versus placebo in treatment-naive, early stage chronic lymphocytic leukemia.
    Blood. 2021 Nov 10. pii: 477942. doi: 10.1182/blood.2021010845.
    PubMed     Abstract available


  227. HASLE H, Kline RM, Kjeldsen E, Nik-Abdul-Rashid NF, et al
    Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Blood. 2021 Nov 10. pii: 477943. doi: 10.1182/blood.2021011463.
    PubMed     Abstract available


  228. FENG Y, Feng W
    Numerous ring sideroblasts in chronic neutrophilic leukemia.
    Blood. 2021;138:1783.
    PubMed    


  229. HERISHANU Y, Perry C
    COVID-19 in patients with CLL: how can we change the odds?
    Blood. 2021;138:1652-1653.
    PubMed    


  230. ROEKER LE, Eyre TA, Thompson MC, Lamanna N, et al
    COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
    Blood. 2021;138:1768-1773.
    PubMed    


  231. HEUSER M, Freeman SD, Ossenkoppele GJ, Buccisano F, et al
    2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.
    Blood. 2021 Nov 1. pii: 477736. doi: 10.1182/blood.2021013626.
    PubMed     Abstract available


    October 2021
  232. CARTER BZ, Tao W, Mak PY, Ostermann LB, et al
    Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
    Blood. 2021;138:1637-1641.
    PubMed    


  233. KOGURE Y, Kameda T, Koya J, Yoshimitsu M, et al
    Whole-genome landscape of adult T-cell leukemia/lymphoma.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01784-5. doi: 10.1182/blood.2021013568.
    PubMed     Abstract available


  234. SCHNOEDER TM, Schwarzer A, Jayavelu AK, Hsu CJ, et al
    PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01783-3. doi: 10.1182/blood.2021012778.
    PubMed     Abstract available


  235. YASUDA T, Sanada M, Kawazu M, Kojima S, et al
    Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
    Blood. 2021 Oct 25. pii: S0006-4971(21)01785-7. doi: 10.1182/blood.2021011921.
    PubMed     Abstract available


  236. ZHAO Y, Wang E
    Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder.
    Blood. 2021;138:1510.
    PubMed    


  237. HAUER J, Fischer U, Borkhardt A
    Toward prevention of childhood ALL by early-life immune training.
    Blood. 2021;138:1412-1428.
    PubMed     Abstract available


  238. JEBARAJ BMC, Muller A, Dheenadayalan RP, Endres S, et al
    Evaluation of vecabrutinib as a model for non-covalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
    Blood. 2021 Oct 18. pii: 477372. doi: 10.1182/blood.2021011516.
    PubMed     Abstract available


  239. KOLIJN PMM, Saberi Hosnijeh F, Spath F, Hengeveld PJ, et al
    HIGH-RISK SUBTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA ARE DETECTABLE AS EARLY AS 16 YEARS PRIOR TO DIAGNOSIS.
    Blood. 2021 Oct 18. pii: 477373. doi: 10.1182/blood.2021012890.
    PubMed     Abstract available


  240. TRINH BQ, Ummarino S, Zhang Y, Ebralidze AK, et al
    Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.
    Blood. 2021;138:1331-1344.
    PubMed     Abstract available


  241. FISHMAN H, Madiwale S, Geron I, Bari V, et al
    ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors.
    Blood. 2021 Oct 8. pii: 477216. doi: 10.1182/blood.2020010405.
    PubMed     Abstract available


  242. PROSSER AL, Li W
    Salmon-colored granules in the leukemic blasts of B-lymphoblastic leukemia with iAMP21.
    Blood. 2021;138:1282.
    PubMed    


    September 2021
  243. SIERRA J, Nomdedeu JF
    CEBPA bZip mutations: just a single shot.
    Blood. 2021;138:1091-1092.
    PubMed    


  244. XU D, Naresh KN
    Leukemic presentation of a highly aggressive ALK-negative anaplastic large cell lymphoma.
    Blood. 2021;138:1198.
    PubMed    


  245. STEPHENS DM, Byrd JC
    Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.
    Blood. 2021;138:1099-1109.
    PubMed     Abstract available


  246. TARLOCK K, Lamble AJ, Wang YC, Gerbing RB, et al
    CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Blood. 2021;138:1137-1147.
    PubMed     Abstract available


  247. ALEJO-VALLE O, Weigert K, Bhayadia R, Ng M, et al
    The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.
    Blood. 2021 Sep 27. pii: 477055. doi: 10.1182/blood.2021012231.
    PubMed     Abstract available


  248. PALLASCH CP
    Cell cycle control in Richter transformation.
    Blood. 2021;138:1005-1007.
    PubMed    


  249. HAN C, Ntziachristos P
    T-ALL and the talented Mr IL7Ralpha.
    Blood. 2021;138:1003-1004.
    PubMed    


  250. YU X, Munoz-Sagredo L, Streule K, Muschong P, et al
    CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues.
    Blood. 2021;138:1067-1080.
    PubMed     Abstract available


  251. CHAKRABORTY S, Martines C, Porro F, Fortunati I, et al
    B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.
    Blood. 2021;138:1053-1066.
    PubMed     Abstract available


  252. DEANGELO DJ, Jonas BA, Liesveld JL, Bixby DL, et al
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
    Blood. 2021 Sep 20. pii: 476977. doi: 10.1182/blood.2021010721.
    PubMed     Abstract available


  253. BERMAN E
    How I Treat Chronic Phase Chronic Myelogenous Leukemia.
    Blood. 2021 Sep 16. pii: 476939. doi: 10.1182/blood.2021011722.
    PubMed     Abstract available


  254. PAIETTA E, Roberts KG, Wang V, Gu Z, et al
    Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
    Blood. 2021;138:948-958.
    PubMed     Abstract available


  255. AMAYA M, Inguva A, Pei S, Jones CL, et al
    The STAT3-MYC Axis Promotes Survival of Leukemia Stem Cells by Regulating SLC1A5 and Oxidative Phosphorylation.
    Blood. 2021 Sep 15. pii: 476917. doi: 10.1182/blood.2021013201.
    PubMed     Abstract available


  256. SAMARAWEERA SE, Wang PP, Li KL, Casolari DA, et al
    Childhood Acute Myeloid Leukemia shows a high level of germline predisposition.
    Blood. 2021 Sep 14. pii: 476894. doi: 10.1182/blood.2021012666.
    PubMed    


  257. ROSSOFF J, Baggott C, Prabhu S, Pacenta HL, et al
    Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia.
    Blood. 2021 Sep 9. pii: 476839. doi: 10.1182/blood.2021012392.
    PubMed    


  258. MA S, Seymour JF, Brander DM, Kipps TJ, et al
    Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
    Blood. 2021;138:836-846.
    PubMed     Abstract available


  259. DAVIS AG, Johnson DT, Zheng D, Wang R, et al
    Alternative polyadenylation dysregulation contributes to the differentiation block of acute myeloid leukemia.
    Blood. 2021 Sep 5. pii: 476791. doi: 10.1182/blood.2020005693.
    PubMed     Abstract available


  260. MEIJERINK JPP
    BCL11B, the Cerberus of human leukemia.
    Blood. 2021;138:741-743.
    PubMed    


  261. SILVA O, Kurzer J
    Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations.
    Blood. 2021;138:818.
    PubMed    


  262. IMGRUET MK, Lutze J, An N, Hu B, et al
    Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.
    Blood. 2021;138:790-805.
    PubMed     Abstract available


    August 2021
  263. HERLING M, Wahnschaffe L
    Altered epigenetics at the center of NK-LGL leukemia.
    Blood. 2021;138:589-591.
    PubMed    


  264. WHEAT JC, Steidl U
    Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.
    Blood. 2021;138:625-636.
    PubMed     Abstract available


  265. JANN JC, Tothova Z
    Cohesin mutations in myeloid malignancies.
    Blood. 2021;138:649-661.
    PubMed     Abstract available


  266. QING Y, Su R, Chen J
    RNA modifications in hematopoietic malignancies: a new research frontier.
    Blood. 2021;138:637-648.
    PubMed     Abstract available


  267. MESSLING JE, Agger K, Andersen KL, Kromer K, et al
    Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
    Blood. 2021 Aug 25. pii: 476529. doi: 10.1182/blood.2021012629.
    PubMed     Abstract available


  268. ASTOLFI A, Masetti R, Indio V, Bertuccio SN, et al
    Torque Teno Mini Virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
    Blood. 2021 Aug 25. pii: 476664. doi: 10.1182/blood.2021011677.
    PubMed    


  269. ZANETTI C, Kumar R, Ender J, Godavarthy PS, et al
    The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13.
    Blood. 2021 Aug 23. pii: 476652. doi: 10.1182/blood.2021011557.
    PubMed     Abstract available


  270. DERECKA M
    AML onco-niche: villain or ally?
    Blood. 2021;138:504-506.
    PubMed    


  271. BURGER JA
    CLL cells are moved by the MARCKS brothers.
    Blood. 2021;138:503-504.
    PubMed    


  272. SCHILLER G
    A slow-go prognosis for older patients with newly diagnosed AML.
    Blood. 2021;138:501-502.
    PubMed    



  273. Genetic decision model for fit older AML patients.
    Blood. 2021;138:585.
    PubMed    


  274. ITZYKSON R, Fournier E, Berthon C, Rollig C, et al
    Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.
    Blood. 2021;138:507-519.
    PubMed     Abstract available


  275. WUDHIKARN K, Flynn JR, Riviere I, Gonen M, et al
    Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy.
    Blood. 2021;138:531-543.
    PubMed     Abstract available


  276. BECKMANN L, Berg V, Dickhut C, Sun C, et al
    MARCKS affects cell motility and response to BTK inhibitors in CLL.
    Blood. 2021;138:544-556.
    PubMed     Abstract available


  277. CORTES J, Apperley JF, Lomaia E, Moiraghi B, et al
    Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial.
    Blood. 2021 Aug 18. pii: 476603. doi: 10.1182/blood.2021012082.
    PubMed     Abstract available


  278. GUO D, Zhao Y, Wang N, You N, et al
    GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
    Blood. 2021;138:464-479.
    PubMed     Abstract available


  279. ALVES DA SILVA PH, Xing S, Kotini AG, Papapetrou EP, et al
    MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.
    Blood. 2021 Aug 6. pii: 476528. doi: 10.1182/blood.2021011619.
    PubMed     Abstract available


  280. YANG S, Zhu XN, Zhang HL, Yang Q, et al
    ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells.
    Blood. 2021 Aug 6. pii: 476526. doi: 10.1182/blood.2020010400.
    PubMed     Abstract available


  281. SORROR ML, Storer BE, Fathi AT, Brunner A, et al
    Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
    Blood. 2021;138:387-400.
    PubMed     Abstract available


    July 2021
  282. HALSEY C, Escherich G
    A "Goldilocks" approach to CNS leukemia is needed.
    Blood. 2021;138:288-289.
    PubMed    


  283. SAUER T, Parikh K, Sharma S, Omer B, et al
    CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
    Blood. 2021;138:318-330.
    PubMed     Abstract available


  284. TAUBE F, Georgi JA, Kramer M, Stasik S, et al
    CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.
    Blood. 2021 Jul 28. pii: 476465. doi: 10.1182/blood.2020009680.
    PubMed     Abstract available


  285. KOLLMANN S, Grausenburger R, Klampfl T, Prchal-Murphy M, et al
    A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells.
    Blood. 2021 Jul 28. pii: 476469. doi: 10.1182/blood.2021010980.
    PubMed     Abstract available


  286. PUZZOLO MC, Radice G, Peragine N, de Propris MS, et al
    Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Blood. 2021 Jul 23. pii: 476452. doi: 10.1182/blood.2021011822.
    PubMed    


  287. GOOPTU M, Romee R, St Martin A, Arora M, et al
    HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
    Blood. 2021;138:273-282.
    PubMed     Abstract available


  288. LEE JB, Khan DH, Hurren R, Xu M, et al
    Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.
    Blood. 2021;138:234-245.
    PubMed     Abstract available


  289. MORANDE PE, Yan XJ, Sepulveda J, Seija N, et al
    AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms.
    Blood. 2021;138:246-258.
    PubMed     Abstract available


  290. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    PubMed     Abstract available


  291. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    PubMed     Abstract available


  292. KUTSCH N
    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.
    PubMed    


  293. PARIKH SA, Rabe KG, Kay NE, Call TG, et al
    The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.
    Blood. 2021;138:149-159.
    PubMed     Abstract available


  294. MULET-LAZARO R, van Herk S, Erpelinck C, Bindels E, et al
    Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
    Blood. 2021;138:160-177.
    PubMed     Abstract available


  295. ZHENG W, Wei J, Zebley CC, Jones LL, et al
    Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL.
    Blood. 2021;138:122-135.
    PubMed     Abstract available


  296. KRANC KR
    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.
    PubMed    


  297. LINLEY AJ, Slupsky JR
    Poor prognosis is ZAP70'ed into focus in CLL.
    Blood. 2021;137:3586-3587.
    PubMed    


    June 2021
  298. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    PubMed     Abstract available


  299. TABE Y, Konopleva M
    Break the lifeline of AML cells.
    Blood. 2021;137:3465-3467.
    PubMed    


  300. MORENO C
    Autoimmune cytopenia and CLL ride together.
    Blood. 2021;137:3464-3465.
    PubMed    


  301. VITALE C, Salvetti C, Griggio V, Porrazzo M, et al
    Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Blood. 2021;137:3507-3517.
    PubMed     Abstract available


  302. MULLER MR
    A new option for Richter syndrome.
    Blood. 2021;137:3318-3319.
    PubMed    


  303. SMOLEJ L
    On the road to optimized BTK inhibition in CLL.
    Blood. 2021;137:3313-3314.
    PubMed    


  304. LOKE J, Cockerill PN
    Unravelling the apoptotic machinery in CMML.
    Blood. 2021;137:3321-3322.
    PubMed    


  305. IANNELLO A, Vitale N, Coma S, Arruga F, et al
    Synergistic efficacy of the dual PI3K-delta/gamma inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
    Blood. 2021;137:3378-3389.
    PubMed     Abstract available


  306. SEVIN M, Debeurme F, Laplane L, Badel S, et al
    Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.
    Blood. 2021;137:3390-3402.
    PubMed     Abstract available


  307. VAISITTI T, Arruga F, Vitale N, Lee TT, et al
    ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Blood. 2021;137:3365-3377.
    PubMed     Abstract available


  308. KATERNDAHL CDS, Rogers ORS, Day RB, Cai MA, et al
    Tumor suppressor function of Gata2 in Acute Promyelocytic Leukemia.
    Blood. 2021 Jun 14. pii: 476182. doi: 10.1182/blood.2021011758.
    PubMed     Abstract available


  309. RUBNITZ JE, Kaspers GJL
    How I treat pediatric acute myeloid leukemia.
    Blood. 2021 Jun 11. pii: 476140. doi: 10.1182/blood.2021011694.
    PubMed     Abstract available


  310. LV K, Ren JG, Han X, Gui J, et al
    Depalmitoylation Rewires FLT3-ITD Signaling and Exacerbates Leukemia Progression.
    Blood. 2021 Jun 10. pii: 476131. doi: 10.1182/blood.2021011582.
    PubMed     Abstract available


  311. MALOUF C, Antunes ETB, O'Dwyer M, Jakobczyk H, et al
    MiR-130b and miR-128a are essential lineage-specific co-drivers of t(4;11) MLL-AF4 acute leukemia.
    Blood. 2021 Jun 10. pii: 476129. doi: 10.1182/blood.2020006610.
    PubMed     Abstract available


  312. CHANG Y, Min J, Jarusiewicz J, Actis M, et al
    Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Blood. 2021 Jun 10. pii: 476126. doi: 10.1182/blood.2020006846.
    PubMed     Abstract available


  313. EICHHORST B
    Vaccination against COVID-19: a challenge in CLL.
    Blood. 2021;137:3153-3154.
    PubMed    


  314. WILLIAMS KM
    Checkpoint-blocked T cells checkmate AML.
    Blood. 2021;137:3155-3156.
    PubMed    


  315. HERLING M, Braun T
    Tracing the roots of CLPD-NK by TET2 and STAT3.
    Blood. 2021;137:3156-3158.
    PubMed    


  316. YUAN Y, Boyle S
    All that glitters is not gold: pseudoplatelets associated with tumour lysis in high-blast-count AML.
    Blood. 2021;137:3310.
    PubMed    


  317. PENTER L, Zhang Y, Savell A, Huang T, et al
    Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
    Blood. 2021;137:3212-3217.
    PubMed     Abstract available


  318. FOSTER MC, Savoldo B, Lau W, Rubinos C, et al
    Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Blood. 2021;137:3306-3309.
    PubMed    


  319. BOLDRIN E, Gaffo E, Niedermayer A, Boer JM, et al
    MicroRNA-497/195 is tumor-suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
    Blood. 2021 Jun 7. pii: 476100. doi: 10.1182/blood.2020007591.
    PubMed     Abstract available


  320. JONES RJ, DeBaun MR
    Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both or neither.
    Blood. 2021 Jun 3. pii: 476065. doi: 10.1182/blood.2021011488.
    PubMed     Abstract available


  321. TANAKA T, Morita K, Wang F, Loghavi S, et al
    Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).
    Blood. 2021 Jun 3. pii: 476064. doi: 10.1182/blood.2020010483.
    PubMed     Abstract available


  322. KORTYLEWSKI M
    Revisiting TLR9 as a target for CLL therapy.
    Blood. 2021;137:3006-3008.
    PubMed    


  323. WERMKE M, Kraus S, Ehninger A, Bargou RC, et al
    Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.
    Blood. 2021;137:3145-3148.
    PubMed    


  324. SOMASUNDARAM R, Jensen CT, Tingvall-Gustafsson J, Ahsberg J, et al
    EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.
    Blood. 2021;137:3037-3049.
    PubMed     Abstract available


  325. DUAULT C, Kumar A, Taghi Khani A, Lee SJ, et al
    Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-risk B- and T- cell Acute Lymphoblastic Leukemia.
    Blood. 2021 Jun 2. pii: 476053. doi: 10.1182/blood.2020009871.
    PubMed     Abstract available


  326. AWADA H, Durmaz A, Gurnari C, Kishtagari A, et al
    Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.
    Blood. 2021 Jun 1. pii: 476049. doi: 10.1182/blood.2020010603.
    PubMed     Abstract available


  327. STEVENSON FK, Forconi F, Kipps TJ
    Exploring the Pathways to Chronic Lymphocytic Leukemia.
    Blood. 2021 Jun 1. pii: 476048. doi: 10.1182/blood.2020010029.
    PubMed     Abstract available


  328. THOMS JAI, Truong P, Subramanian S, Knezevic K, et al
    Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
    Blood. 2021 Jun 1. pii: 476046. doi: 10.1182/blood.2020009707.
    PubMed     Abstract available


    May 2021
  329. GHIA P, Stamatopoulos K
    In CLL, epigenetics also points to the BCR.
    Blood. 2021;137:2863-2865.
    PubMed    


  330. MASS J, Park DC
    Posttransplant T lymphoblastic lymphoma mimicking Burkitt lymphoma.
    Blood. 2021;137:3002.
    PubMed    


  331. COORENS THH, Collord G, Lu W, Mitchell E, et al
    Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
    Blood. 2021;137:2992-2997.
    PubMed    


  332. WANG D, Wang J, Hu G, Wang W, et al
    A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
    Blood. 2021;137:2890-2901.
    PubMed     Abstract available


  333. FOWLER N
    Kinase inhibitors in CLL: drawing the roadmap.
    Blood. 2021;137:2717-2719.
    PubMed    


  334. GANSER A
    What can Heraclitus tell us about AML?
    Blood. 2021;137:2719-2720.
    PubMed    


  335. LIU H
    Basophilic myeloblasts: a clue for CML blast phase.
    Blood. 2021;137:2852.
    PubMed    


  336. MUSANI R, Chang H
    Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML.
    Blood. 2021;137:2853.
    PubMed    


  337. DUCHMANN M, Micol JB, Duployez N, Raffoux E, et al
    Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study.
    Blood. 2021;137:2827-2837.
    PubMed     Abstract available


  338. THIJSSEN R, Diepstraten ST, Moujalled D, Chew E, et al
    Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Blood. 2021;137:2721-2735.
    PubMed     Abstract available


  339. MATO AR, Ghosh N, Schuster SJ, Lamanna N, et al
    Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kdelta inhibitor therapy.
    Blood. 2021;137:2817-2826.
    PubMed     Abstract available


  340. BORELLA G, Da Ros A, Borile G, Porcu E, et al
    Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course.
    Blood. 2021 May 19. pii: 475978. doi: 10.1182/blood.2020009845.
    PubMed     Abstract available


  341. VAN DER KOUWE E, Heller G, Czibere A, Pulikkan JA, et al
    Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
    Blood. 2021 May 19. pii: 475975. doi: 10.1182/blood.2020008971.
    PubMed     Abstract available


  342. BISHOP DC, Clancy LE, Simms R, Burgess J, et al
    Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.
    Blood. 2021 May 19. pii: 475980. doi: 10.1182/blood.2021010813.
    PubMed     Abstract available


  343. ESCRIBANO SERRAT S, Calo Perez A
    Pure erythroid leukemia.
    Blood. 2021;137:2709.
    PubMed    


  344. TAKEDA MR, Gurbuxani S
    bcr3 PML-RARA: short fusion, small blasts!
    Blood. 2021;137:2708.
    PubMed    


  345. SURAPALLY S, Tenen DG, Pulikkan JA
    Emerging therapies for inv(16) AML.
    Blood. 2021;137:2579-2584.
    PubMed     Abstract available


  346. KIRCHHOFF H, Karsli U, Schoenherr C, Battmer K, et al
    Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
    Blood. 2021;137:2657-2661.
    PubMed     Abstract available


  347. MICKLETHWAITE KP, Gowrishankar K, Gloss BS, Li Z, et al
    Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells.
    Blood. 2021 May 11. pii: 475942. doi: 10.1182/blood.2021010858.
    PubMed     Abstract available


  348. SILVA AP, Almeida ARM, Cachucho A, Neto JL, et al
    Overexpression of wild type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma.
    Blood. 2021 May 10. pii: 475938. doi: 10.1182/blood.2019000553.
    PubMed     Abstract available


  349. WIMMER J, Hurstel R
    Systemic mastocytosis with an associated t(8;21)(q22;q22) acute myeloid leukemia.
    Blood. 2021;137:2564.
    PubMed    


  350. PADI SKR, Kraft AS
    "Root"ing for successful T-ALL treatment.
    Blood. 2021;137:2422-2423.
    PubMed    


  351. GEOFFROY MC, Esnault C, de The H
    Retinoids in hematology: a timely revival?
    Blood. 2021;137:2429-2437.
    PubMed     Abstract available


  352. ANAND P, Guillaumet-Adkins A, Dimitrova V, Yun H, et al
    Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.
    Blood. 2021;137:2463-2480.
    PubMed     Abstract available


    April 2021
  353. ANDRIEU GP, Asnafi V
    Integrated omics approaches to predict T-LBL relapse risk.
    Blood. 2021;137:2280-2282.
    PubMed    


  354. TERRE C, Raggueneau V
    Double insertion in normal karyotype CML.
    Blood. 2021;137:2418.
    PubMed    


  355. SORROR ML, Storer BE, Fathi AT, Brunner AM, et al
    Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.
    Blood. 2021 Apr 28. pii: 475848. doi: 10.1182/blood.2020008812.
    PubMed     Abstract available


  356. CHATZIDIMITRIOU C, Vassilakopoulos TP
    Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
    Blood. 2021;137:2272.
    PubMed    


  357. RINGSHAUSEN I
    IL-9 in CLL: sensing home and settling down!
    Blood. 2021;137:2130-2131.
    PubMed    


  358. SOARES F, Chen B, Lee JB, Ahmed M, et al
    CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
    Blood. 2021;137:2171-2181.
    PubMed     Abstract available


  359. DA SILVA-DIZ V, Cao B, Lancho O, Chiles E, et al
    A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.
    Blood. 2021 Apr 19. pii: 475782. doi: 10.1182/blood.2020008955.
    PubMed     Abstract available


  360. MITTELMAN SD, Kim J, Raca G, Li G, et al
    Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia.
    Blood. 2021 Apr 19. pii: 475790. doi: 10.1182/blood.2021011106.
    PubMed    


  361. LEW TE, Tam CS, Seymour JF
    How I treat chronic lymphocytic leukemia after venetoclax.
    Blood. 2021 Apr 19. pii: 475780. doi: 10.1182/blood.2020008502.
    PubMed     Abstract available


  362. DI GIACOMO D, La Starza R, Gorello P, Pellanera F, et al
    14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T and myeloid immature acute leukemia.
    Blood. 2021 Apr 19. pii: 475778. doi: 10.1182/blood.2020010510.
    PubMed     Abstract available


  363. HERISHANU Y, Avivi I, Aharon A, Shefer G, et al
    Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
    Blood. 2021 Apr 16. pii: 475742. doi: 10.1182/blood.2021011568.
    PubMed     Abstract available


  364. AMES E, Silva O
    Polytypic T-cell prolymphocytic leukemia.
    Blood. 2021;137:2125.
    PubMed    


  365. SANDBERG Y, Weerkamp F
    Charcot-Leyden crystals in chronic eosinophilic leukemia.
    Blood. 2021;137:1985.
    PubMed    


  366. SEFTEL MD
    Has MRD graduated from its adolescence in ALL?
    Blood. 2021;137:1846-1847.
    PubMed    


  367. KENNEDY GA, Tey SK, Buizen L, Varelias A, et al
    A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
    Blood. 2021;137:1970-1979.
    PubMed     Abstract available


  368. GEMENETZI K, Psomopoulos F, Carriles AA, Gounari M, et al
    Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.
    Blood. 2021;137:1895-1904.
    PubMed     Abstract available


  369. SHAH BD, Bishop MR, Oluwole OO, Logan AC, et al
    KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
    Blood. 2021 Apr 7. pii: 475697. doi: 10.1182/blood.2020009098.
    PubMed     Abstract available


  370. WEI AH, Daver N
    Taking aim at IDH in fitter patients with AML.
    Blood. 2021;137:1706-1707.
    PubMed    


  371. SCHWAB C, Roberts K, Boer JM, Gohring G, et al
    SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome.
    Blood. 2021;137:1835-1838.
    PubMed    


  372. STEIN EM, DiNardo CD, Fathi AT, Mims AS, et al
    Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Blood. 2021;137:1792-1803.
    PubMed     Abstract available


    March 2021
  373. IACOBUCCI I, Qu C, Varotto E, Janke LJ, et al
    Modeling and targeting of erythroleukemia by hematopoietic genome editing.
    Blood. 2021;137:1628-1640.
    PubMed     Abstract available


  374. SIMONIN M, Lhermitte L, Dourthe ME, Lengline E, et al
    IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL.
    Blood. 2021;137:1690-1694.
    PubMed    


  375. HOSOKAWA K, Mizumaki H, Yoroidaka T, Maruyama H, et al
    HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia.
    Blood. 2021 Mar 22. pii: 475586. doi: 10.1182/blood.2020010586.
    PubMed    


  376. KOGAN SC
    PML-RARalpha: changing myeloid networks.
    Blood. 2021;137:1439-1440.
    PubMed    


  377. ERNST MPT, Kavelaars FG, Lowenberg B, Valk PJM, et al
    RUNX1 germline variants in RUNX1-mutant AML: how frequent?
    Blood. 2021;137:1428-1431.
    PubMed    


  378. AGATHANGELIDIS A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, et al
    Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
    Blood. 2021;137:1365-1376.
    PubMed     Abstract available


  379. NAZHA A
    Should I rock the boat? When to stop TKIs in CML.
    Blood. 2021;137:1136-1137.
    PubMed    


    February 2021
  380. DE MOERLOOSE B
    CAR-T treatment of pediatric AML: a long and winding road.
    Blood. 2021;137:1004-1006.
    PubMed    


  381. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    PubMed     Abstract available


  382. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    PubMed     Abstract available


  383. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    PubMed     Abstract available


  384. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    PubMed     Abstract available


  385. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    PubMed     Abstract available


  386. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    PubMed     Abstract available


  387. GILL S
    DARTs point the way forward in AML.
    Blood. 2021;137:720-721.
    PubMed    


  388. NG AP
    Unraveling a T-ALL Tapestri.
    Blood. 2021;137:726-727.
    PubMed    


  389. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.
    PubMed    


  390. GRANT S
    Targeting cereblon in AML.
    Blood. 2021;137:584-586.
    PubMed    


  391. BROWN JR
    AKT: a key to RT?
    Blood. 2021;137:582-584.
    PubMed    


  392. KOHLHAAS V, Blakemore SJ, Al-Maarri M, Nickel N, et al
    Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.
    Blood. 2021;137:646-660.
    PubMed     Abstract available


  393. FALINI B, Brunetti L, Martelli MP
    How I diagnose and treat NPM1-mutated AML.
    Blood. 2021;137:589-599.
    PubMed     Abstract available


    January 2021
  394. SHOUVAL R, Soiffer RJ
    Primum non nocere: allo-HSCT for AML in CR1.
    Blood. 2021;137:438-439.
    PubMed    


  395. COHEN AUBART F, Roos-Weil D, Armand M, Marceau-Renaut A, et al
    High frequency of clonal hematopoiesis in Erdheim-Chester disease.
    Blood. 2021;137:485-492.
    PubMed     Abstract available


  396. ZHAO Y, Aldoss I, Qu C, Crawford JC, et al
    Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.
    Blood. 2021;137:471-484.
    PubMed     Abstract available


  397. RIO-MACHIN A, Fitzgibbon J
    Germline ETV6 variants: not ALL created equally.
    Blood. 2021;137:288-289.
    PubMed    


  398. GAUTHIER J, Bezerra ED, Hirayama AV, Fiorenza S, et al
    Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Blood. 2021;137:323-335.
    PubMed     Abstract available


  399. MERTENS D, Kronke J
    Triggering T-cell activity in CLL.
    Blood. 2021;137:150-151.
    PubMed    


  400. MASS J, Alobeid B
    Composite mantle cell lymphoma and small lymphocytic lymphoma in a lymph node.
    Blood. 2021;137:282.
    PubMed    


  401. AL MOOSAWI M, Vercauteren S
    Cerebrospinal fluid with unusual natural killer cell population.
    Blood. 2021;137:281.
    PubMed    


  402. IOANNOU N, Hagner PR, Stokes M, Gandhi AK, et al
    Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Blood. 2021;137:216-231.
    PubMed     Abstract available


  403. CORRE J
    Undetectable MRD can change the deal.
    Blood. 2021;137:5-6.
    PubMed    


  404. KEESHAN K
    Superenhancing AML with Trib1.
    Blood. 2021;137:8-9.
    PubMed    


    December 2020
  405. KAPP-SCHWOERER S, Weber D, Corbacioglu A, Gaidzik VI, et al
    Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
    Blood. 2020;136:3041-3050.
    PubMed     Abstract available


  406. MIAO H, Kim E, Chen D, Purohit T, et al
    Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.
    Blood. 2020;136:2958-2963.
    PubMed    


  407. LIU Y, Panetta JC, Yang W, Karol SE, et al
    Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.
    Blood. 2020;136:2955-2958.
    PubMed    


  408. HASELAGER MV, Kielbassa K, Ter Burg J, Bax DJC, et al
    Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Blood. 2020;136:2918-2926.
    PubMed     Abstract available


  409. OBERBECK S, Schrader A, Warner K, Jungherz D, et al
    Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
    Blood. 2020;136:2786-2802.
    PubMed     Abstract available


  410. SALLMAN DA, McLemore AF, Aldrich AL, Komrokji RS, et al
    TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.
    Blood. 2020;136:2812-2823.
    PubMed     Abstract available


  411. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    PubMed     Abstract available


    November 2020
  412. CORTES J
    How to manage CML patients with comorbidities.
    Blood. 2020;136:2507-2512.
    PubMed     Abstract available


  413. DZAMA MM, Steiner M, Rausch J, Sasca D, et al
    Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Blood. 2020;136:2442-2456.
    PubMed     Abstract available


  414. WATANABE A, Miyake K, Nordlund J, Syvanen AC, et al
    Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.
    Blood. 2020;136:2319-2333.
    PubMed     Abstract available


  415. HANEKAMP D, Ngai LL, Janssen JJ, van de Loosdrecht AA, et al
    Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells.
    Blood. 2020 Nov 10. pii: 474126. doi: 10.1182/blood.2020007150.
    PubMed    


  416. KHANAM T, Sandmann S, Seggewiss J, Ruether CM, et al
    Integrative genomic analysis of pediatric T- cell lymphoblastic lymphoma reveals candidates of clinical significance.
    Blood. 2020 Nov 5. pii: 474099. doi: 10.1182/blood.2020005381.
    PubMed     Abstract available


    July 2020
  417. BLOUIN JM, Ged C, Lalanne M, Lamrissi-Garcia I, et al
    Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
    Blood. 2020 Jul 17. pii: 461423. doi: 10.1182/blood.2020006037.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: